Albumin Infusion: Patients’ Perspectives and the Reality
A single sentence can pinpoint the core of the article, such as, “How do patients understand the true role of albumin within Hong Kong’s healthcare system?”
Free cancer support
What is albumin? Why is it important?
Albumin is the main protein in human plasma, accounting for roughly half of plasma proteins. Its functions go beyond being a simple “nutritional marker” and are vital for physiological balance:
- Maintaining plasma colloid osmotic pressure: Prevents excessive fluid from leaking into tissues, reducing edema.
- Transport functions: Carries fatty acids, hormones, drugs, and bilirubin.
- Antioxidant and buffering roles: Helps the body counteract oxidative stress.
Therefore, when blood albumin levels are low (below 35 g/L), patients are more prone to edema, ascites, poor wound healing, and other complications (Caironi & Gattinoni, 2009).
When is Albumin Infusion Recommended?
Medically, albumin is not a “nutritional supplement” but a blood product. It is mainly indicated in the following situations:
- Cirrhosis with ascites: After paracentesis or dialysis, moderate albumin infusion can reduce the risk of circulatory collapse (Caraceni et al., 2018).
- Severe infection or sepsis: Some critically ill patients may benefit from albumin to stabilize blood pressure.
- Nephrotic syndrome: Temporary supplementation can help when severe hypoalbuminemia causes edema.
- Major surgery or post-trauma blood loss: Sometimes used alongside other fluid therapies.
However, in many clinical scenarios, albumin is not the only option. For example, hypoalbuminemia caused by malnutrition should be addressed by improving nutritional intake rather than solely relying on infusion.
Common Misconceptions Among Patients
Many Hong Kong patients immediately associate “low albumin” with “must get an infusion.” Clinically, several misconceptions exist:
- Albumin equals nutrition?
A drop in albumin does not necessarily mean poor nutrition; it may result from inflammation or chronic illness. - Albumin infusion improves energy?
Albumin is not an energy source, and patients may not feel immediate improvement after infusion. - Albumin has no side effects?
As a blood product, albumin can cause allergic reactions, infection risks, and even increased chances of pulmonary edema (Wilkes & Navickis, 2001).
These misconceptions often lead patients to passively accept treatment without fully understanding its necessity.
The Reality in Hong Kong’s Healthcare System
In Hong Kong public hospitals, albumin is a high-cost medication and generally requires physician assessment and approval. Patients often hear healthcare staff say: “Your albumin is too low, you need an infusion.” Such statements, however, simplify the complex medical decision-making process.
Key challenges for patients include:
- Information asymmetry: Doctors may not have enough time to explain purposes and risks in detail.
- Financial pressure: In private hospitals, albumin is expensive, making it difficult for patients to judge necessity.
- Psychological stress: Hearing “low albumin” can trigger anxiety and perceived severity.
These factors represent the real challenges faced by patients in Hong Kong.
Scientific Evidence and Clinical Controversies
International research has examined the efficacy of albumin infusion extensively:
- Sepsis and critical care: The SAFE trial (2004) found no significant difference in overall survival between albumin and saline, though potential benefits exist in sepsis patients (Finfer et al., 2004).
- Cirrhosis patients: Long-term low-dose albumin therapy may reduce complications, but costs and side effects must be considered (Caraceni et al., 2018).
- General hypoalbuminemia: No sufficient evidence shows that albumin infusion alone improves long-term survival.
Thus, international guidelines generally recommend use in specific circumstances, not routine infusion.
Patient Autonomy and Decision-Making
For Hong Kong patients, albumin infusion involves both medical and autonomy considerations.
- Asking questions: Patients have the right to ask, “Why do I need albumin? Are there alternatives?”
- Understanding risks and benefits: Clarify whether the goal is to “reduce complications” or simply “improve lab results.”
- Family and financial considerations: In private care, patients must weigh cost-effectiveness.
Active patient involvement fosters transparency and reduces unnecessary anxiety.
Real Case Example (Patient Perspective)
“When the doctor told me I needed albumin, I was very scared. He only said, ‘Your level is too low,’ but I didn’t understand why. Later, after asking a few more questions, I learned it was because of my cirrhosis and post-paracentesis fluid loss. Although I accepted it, if the doctor had explained clearly from the start, I wouldn’t have been so worried.”
This highlights how clear communication often impacts patient experience more than the treatment itself.
Information Hong Kong Patients Need
From a patient perspective, Hong Kong society urgently needs:
- Neutral information platforms: Provide scientific explanations about albumin therapy and prevent misinformation.
- Patient education: Help patients understand that low albumin does not always require infusion and that nutritional management is equally important.
- Policy support: Transparent cost information is needed in the public-private healthcare divide.
Conclusion
Albumin infusion is neither a panacea nor a simple “nutritional boost.” For Hong Kong patients, it is a multidimensional issue involving medical, economic, and psychological aspects. Understanding albumin’s functions and limitations, and asking questions during care, embodies true patient-centered decision-making.
Want to know how to choose the most suitable adjuvant therapy for cancer?
Contact our professional team now
References
- Caironi, P., & Gattinoni, L. (2009). The clinical use of albumin: The point of view of a clinician. Critical Care, 13(2), 209. https://doi.org/10.1186/cc7761
- Caraceni, P., Riggio, O., Angeli, P., Alessandria, C., Neri, S., Foschi, F. G., … & Bernardi, M. (2018). Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomized trial. The Lancet, 391(10138), 2417-2429. https://doi.org/10.1016/S0140-6736(18)30840-7
- Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J., & Norton, R. (2004). A comparison of albumin and saline for fluid resuscitation in the intensive care unit. The New England Journal of Medicine, 350(22), 2247-2256. https://doi.org/10.1056/NEJMoa040232
- Wilkes, M. M., & Navickis, R. J. (2001). Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine, 135(3), 149-164. https://doi.org/10.7326/0003-4819-135-3-200108070-00007